Adam J. Waxman, MD
Assistant Professor of Clinical Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
12 South Pavilion
Room #12-174
Philadelphia, PA 19104
3400 Civic Center Blvd
12 South Pavilion
Room #12-174
Philadelphia, PA 19104
Publications
Education:
BA (Chemistry)
New York University, 2007.
MD (Medicine)
Duke University School of Medicine, 2011.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2025.
Permanent linkBA (Chemistry)
New York University, 2007.
MD (Medicine)
Duke University School of Medicine, 2011.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2025.
Description of Clinical Expertise
Multiple MyelomaAmyloidosis
Monoclonal Gammopathies
Paraprotein Mediated Renal Disease
Cryoglobulinemia
Autologous Stem Cell Transplantation
Chronic Lymphocytic Leukemia
Indolent Lymphomas
Description of Research Expertise
Multiple Myeloma and Amyloidosis Clinical TrialsSelected Publications
Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman AJ, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA: CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nature Medicine 32(2): 702-716. Feb 2026.Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S.: Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma Blood Advances 10(4): 1395-1399, Dec 2025.
Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali ZS, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S.: Outcomes of relapse after teclistamab therapy in multiple myeloma. Blood Cancer Journal 15(1): 193, November 2025.
Yu K, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S.: Outcomes of relapse after teclistamab therapy in multiple myeloma. Blood Cancer J 15(1), Nov 2025.
Kyle L. Yu, Matthew Ho, Luca Paruzzo, Federico Stella, Heta Patel, Zainul S. Hasanali, Shivani Kapur, Adam J. Waxman, Dan T. Vogl, Edward A. Stadtmauer, Joseph A. Fraietta, Marco Ruella, Adam D. Cohen, Alfred L. Garfall & Sandra Susanibar-Adaniya: Outcomes of relapse after teclistamab therapy in multiple myeloma. Blood cancer journal 15(1), Nov 2025.
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S.: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica 110(6): 1436-1442, June 2025.
Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ.: Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. European Journal of Haematology 114(3): 443-447. March 2025.
Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E.: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplant 60(1): 64-68, Jan 2025 Notes: doi: 10.1038/s41409-024-02455-4. Online ahead of print.
Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E.: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplant 60(1): 64-68, January 2025.
Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ: Safety and Efficacy of teclistamab in Patients with Relapsed or Refractory AL Amyloidosis. European Journal of Haematology 114(3): 443-447, Nov 2024 Notes: doi: 10.1111/ejh.14348. Online ahead of print.